Triple Incretin Agonists (Glp 1 Gip Glucagon) For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Combination agonists targeting multiple incretin receptors (GLP-1, GIP, and glucagon) represent a novel approach to treating neurodegenerative diseases. These multi-receptor agonists leverage synergistic effects on glucose metabolism, neuroprotection, and neuroinflammation. [1]
| Compound | Company | Stage | Key Features | [2]
|----------|---------|-------|--------------| [3]
| GT-1 | -- | Preclinical | Balanced triple agonist | [4]
| HM15211 | -- | Phase 1 | GIP/GLP-1/glucagon | [5]
| BI-456906 | Boehringer | Phase 2 | GIP/GLP-1/glucagon | [6]
Triple agonists may provide: [7]
Potential benefits:
Emerging evidence suggests:
The study of Triple Incretin Agonists (Glp 1 Gip Glucagon) For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Athauda D, Foltynie T. The glucagon-like peptide 1 analogue exenatide in Parkinson's disease: a randomised controlled study. 2018. ↩︎
Yildirim Dow E, et al. The role of GIP in the brain. 2020. ↩︎
Yang L, et al. Tirzepatide: a novel dual GIP/GLP-1 receptor agonist for the treatment of type 2 diabetes and obesity. 2022. ↩︎
Salameh TS, et al. GLP-1 receptor agonists and neurodegenerative disease: new perspectives on molecular mechanisms. 2023. ↩︎
Mulvihill EE. GIP receptor biology and therapeutic potential. 2024. ↩︎
Belsi E, et al. Triple GLP-1/GIP/Glucagon agonists: a new frontier in metabolic disease treatment. 2024. ↩︎
Finan B, et al. Chemical hybridization of glucagon and GLP-1 results in therapeutic agents for metabolic disease. 2025. ↩︎